Oppenheimer raised the firm’s price target on enGene (ENGN) to $33 from $30 and keeps an Outperform rating on the shares. The firm believes the reveal from the pivotal LEGEND trial in high-risk NMIBC is not only impressive in its own right – highlighted by detalimogene’s 62% 6-month complete response rate – but also addresses the market’s skepticism following last September’s initial showing, which preceded changes that brought the trial’s design closer to current standards for this indication.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- enGene price target raised to $10 from $4 at UBS
- Cautious Hold Rating for enGene Holdings Amid Competitive Trial Results and Market Uncertainty
- enGene price target raised to $21 from $18 at Citizens JMP
- Here’s Why enGene Holdings Stock Is Soaring Today
- Midday Fly By: SoftBank exits Nvidia, CoreWeave cuts guidance